Company intelligence / Profile preview
Renatus
Daejeon, Daejeon, South Korearenatustx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Renatus has developed a proprietary technology to normalize cellular cholesterol levels using novel cyclodextrins and small molecules. Their lead candidate, RN-005, has shown efficacy in preclinical models of chronic kidney disease. The company holds patents for its approach and was selected for several biotech innovation programs/grants. No human clinical data reported as of June 2025.
- Therapeutic areas
- NeurologyCardiovascularNephrology
- Modalities
- Small moleculeCyclodextrin-based therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
CarbohydeMerckKHIDI Hospital-Based Business Innovation CenterIncheon Startup Park Scale-Up Challenge LabMinistry of SMEs & Startups Startup-Focused University Program
Beyond the preview
Go deeper on Renatus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Renatus.